Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy

NCT01632306 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01632306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01632306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2013
Completion date
June 30, 2015
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer